NJ-based Novartis to lay off 427 as drug patent expires
Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...
Daily Voice11h
Pharma Giant Cutting 400+ More NJ Jobs Ahead Of Major Drug Patent's Expiration
Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...
Zacks Investment Research on MSN11h
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Fierce Pharma13h
Novartis links music and science in corporate campaign tied to Eurovision sponsorship
Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Managed Healthcare Executive14h
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
BioSpace14h
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
Fierce Pharma14h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
The American Journal of Managed Care15h
FDA Approves Oral Iptacopan for C3 Glomerulopathy
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
The American Journal of Managed Care15h
Overcoming CAR T Manufacturing Failure in LBCL
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...
Novartis1d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Novartis gets third FDA approval for oral Fabhalta
Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the ...